Alkermes plc. Other Accrued Liabilities, Current
Alkermes plc. (ALKS) had Other Accrued Liabilities, Current of $126.21 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Notes
us-gaap:OtherAccruedLiabilitiesCurrent · last filed 2026-07-28
- 2026-06-30: Other Accrued Liabilities, Current $126.21M.
- 2026-03-31: Other Accrued Liabilities, Current $136.79M.
- 2025-12-31: Other Accrued Liabilities, Current $99.17M.
- 2025-09-30: Other Accrued Liabilities, Current $79.79M.
| Period end | Other Accrued Liabilities, Current | Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $126.21M 10-Q · filed 2026-07-28 | |
| 2026-03-31 | $136.79M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $99.17M 10-Q · filed 2026-07-28 | |
| 2025-09-30 | $79.79M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $90.00M 10-Q · filed 2025-07-29 | |
| 2025-03-31 | $83.09M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $68.74M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $67.26M 10-Q · filed 2024-10-24 | |
| 2024-06-30 | $85.64M 10-Q · filed 2024-07-24 | |
| 2024-03-31 | $81.59M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $91.81M 10-K · filed 2025-02-12 | |
| 2023-09-30 | $88.45M 10-Q · filed 2023-10-25 | |
| 2023-06-30 | $98.35M 10-Q · filed 2023-07-26 | |
| 2023-03-31 | $105.30M 10-Q · filed 2023-04-26 | |
| 2022-12-31 | $108.16M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $117.06M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $93.90M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $91.02M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $75.51M 10-K · filed 2023-02-16 | |
| 2021-09-30 | $101.44M 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $68.05M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $62.52M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $76.08M 10-K · filed 2022-02-16 | |
| 2020-09-30 | $53.77M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $65.77M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $64.59M 10-Q · filed 2020-04-29 | |
| 2019-12-31 | $92.80M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $76.41M 10-Q · filed 2019-10-23 | |
| 2019-06-30 | $75.99M 10-Q · filed 2019-07-25 | |
| 2019-03-31 | $75.62M 10-Q · filed 2019-04-25 | |
| 2018-12-31 | $73.47M 10-K · filed 2020-02-13 | |
| 2018-09-30 | $59.38M 10-Q · filed 2018-10-23 | |
| 2018-06-30 | $53.53M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $51.01M 10-Q · filed 2018-04-26 | |
| 2017-12-31 | $64.94M 10-K · filed 2019-02-15 | |
| 2017-09-30 | $57.22M 10-Q · filed 2017-10-26 | |
| 2017-06-30 | $54.05M 10-Q · filed 2017-07-27 | |
| 2017-03-31 | $60.26M 10-Q · filed 2017-04-27 | |
| 2016-12-31 | $54.19M 10-K · filed 2018-02-16 | $53.29M 10-K · filed 2017-02-17 |
| 2016-09-30 | $50.79M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $49.13M 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $48.15M 10-Q · filed 2016-04-28 | |
| 2015-12-31 | $61.32M 10-K · filed 2017-02-17 | $62.51M 10-K · filed 2016-02-25 |
| 2015-09-30 | $54.08M 10-Q · filed 2015-10-29 | |
| 2015-06-30 | $51.40M 10-Q · filed 2015-07-30 | |
| 2015-03-31 | $42.80M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $39.46M 10-K · filed 2016-02-25 | $50.06M 10-K · filed 2015-02-24 |
| 2014-09-30 | $43.71M 10-Q · filed 2014-10-29 | |
| 2014-06-30 | $40.41M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $36.71M 10-Q · filed 2014-04-30 | |
| 2013-12-31 | $36.28M 10-K · filed 2015-02-24 | |
| 2013-09-30 | $33.50M 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $33.18M 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $27.59M 10-KT · filed 2014-02-27 | $27.23M 10-K · filed 2013-05-23 |
| 2012-12-31 | $28.94M 10-Q · filed 2013-01-31 | |
| 2012-09-30 | $28.55M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $29.57M 10-Q · filed 2012-07-26 | |
| 2012-03-31 | $33.26M 10-K · filed 2013-05-23 | |
| 2011-03-31 | $18.18M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |